Skip to main content
Log in

Hormone refractory prostate cancer and fibroblast growth factor receptor

  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

In prostate cancer, a distinct series of alterations in the fibroblast growth factor (FGF) family occurs during the progression from a hormone-dependent to independent state that disrupts communication between stroma and epithelium and results in autonomy of cancer cells. Changes include (i) loss of FGFR2lllb, which binds stromal-derived FGF-7, which promotes growth, growth limitation and differentiation and (ii) activation of FGFR1, the expression of which is normally limited to stroma, along with activation of FGFs that act on FGFR1 in an autocrine manner. Transfection of the FGFR2lllb isoform into hormone-independent prostate cancer cells not only causes growth inhibition, but also induces differentiation. However, introduction of FGFR1 by transfection in hormone-dependent prostate cancer cells accelerates their progression to malignancy. These results suggest distinct targets for therapy aimed at both inhibition of the malignant phenotype and restoration of homeostasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

FGF:

Fibroblast growth factor

FGFR:

Fibroblast growth factor receptor

References

  1. Yan G, Fukabori Y, Nikolaropoulos S,et al: Heparinbinding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin.Mol Endocrinol 6:2123–2128, 1992.

    Article  PubMed  CAS  Google Scholar 

  2. Sugimura Y, Foster BA,et al: Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate.Int J Dev Biol 40:941–951, 1996.

    PubMed  CAS  Google Scholar 

  3. Lu W, Luo Y, Kan M,et al: Fibroblast growth factor-10; A second candidate stromal to epithelial cell andromedin in prostate.J Biol Chem 274:12827–12834, 1999.

    Article  PubMed  CAS  Google Scholar 

  4. Yan G, Fukabori Y, McBride G,et al: Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy.Mol Cell Biol 13:4513–4522, 1993.

    PubMed  CAS  Google Scholar 

  5. Feng S, Wang F, Matsubara A,et al: Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells.Cancer Res 57:5369–5378, 1997.

    PubMed  CAS  Google Scholar 

  6. Yan G, McBride G, McKeehan WL: Exon skipping causes alteration of the COOH-terminus and deletion of the phospholipase C gamma 1 interaction site in the FGF receptor 2 kinase in normal prostate epithelial cells.Biochem Biophys Res Commun 194:512–518, 1993.

    Article  PubMed  CAS  Google Scholar 

  7. Wang F, Kan M, Xu J,et al: Ligand-specific structural domains in the fibroblast growth factor receptor.J Biol Chem 270:10222–10230, 1995.

    Article  PubMed  CAS  Google Scholar 

  8. McKeehan WL, Adams PS, Fast D: Different hormonal requirements for androgen-independent growth of normal and tumor epithelial cells from rat prostate.In Vitro Cell Devel Biol 23:147–152, 1987.

    Article  CAS  Google Scholar 

  9. Mansson PE, Adams P, Kan M,et al: Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors.Cancer Res 49:2485–2494, 1989.

    PubMed  CAS  Google Scholar 

  10. Isaacs JT: Development and characteristics of the available animal model systems for the study of prostate cancer. In: N Bruchovsky WA, Gardner MI, Resnick PP Karr, DS Coffey eds, Current Concepts and Approaches to the Study of Prostate Cancer, New York, Alan R. Liss, Inc, pp573–576, 1987.

    Google Scholar 

  11. Matsubara A, Kan M, Feng S,et al: Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2.Cancer Res 58:1509–1514, 1998.

    PubMed  CAS  Google Scholar 

  12. Kan M, Shi EG, McKeehan WL: Identification and assay of fibroblast growth factor receptors.Methods Enzymol 198:158–171, 1991.

    Article  PubMed  CAS  Google Scholar 

  13. Ornitz DM, Xu J, Colvin JS,et al: Receptor specificity of the fibroblast growth factor family.J Biol Chem 271:15292–15297, 1996.

    Article  PubMed  CAS  Google Scholar 

  14. Rabin SJ, Cleghon V, Kaplan DR: SNT, a differentiation-specific target of neurotrophic factor-induced tyrosine kinase activity in neurons and PC12 cells.Mol Cell Biol 13:2203–2213, 1993.

    PubMed  CAS  Google Scholar 

  15. Wang JK, Xu H, Li HC,et al: Broadly expressed SNT-like proteins link FGF receptor stimulation to activators of Ras.Oncogene 13:721–729, 1996.

    PubMed  CAS  Google Scholar 

  16. Ong SH, Goh KC, Lim YP,et al: SUC1-associated neurotrophic factor target (SNT) protein is a major FGF-stimulated tyrosine phosphorylated 90-kDa protein which binds to the SH2 domain of GRB2.Biochem Biophys Res Commun 225:1021–1026, 1996.

    Article  PubMed  CAS  Google Scholar 

  17. Su WC, Kitagawa M, Xue N,et al: Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.Nature 386:288–292, 1997.

    Article  PubMed  CAS  Google Scholar 

  18. Carstens RP, Eaton JV, Krigman HR,et al: Alternative splicing of fibloblast growth factor receptor 2 (FGF-R2) in human prostate cancer.Oncogene 15:3059–3065, 1997.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

About this article

Cite this article

Matsubara, A., Yasumoto, H. & Usui, T. Hormone refractory prostate cancer and fibroblast growth factor receptor. Breast Cancer 6, 320–324 (1999). https://doi.org/10.1007/BF02966447

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02966447

Key words

Navigation